The pharmaceutical giant just extended the lifespan of one of its top drugs.

Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug showed benefit as a second-line therapy in a Phase III trial. In the MagnetisMM-5 study (NCT05020236),

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, eleventh-hour settlements with two of the three generic drugmakers | Eleventh-hour settlements with two of the three generic drugmakers involved could bode well for both Pfizer and its ATTR competitor BridgeBio,

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark.

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent activity suggests that the FDA is taking a closer look at how pharmaceutical companies present risk and benefit information in digital formats,

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne

Pfizer said on Wednesday its drug Elrexfio met the main goal in a ​late-stage trial that tested the blood cancer ‌treatment in patients who received at least one prior line of treatment.

Pfizer has spent the past few years trying to convince investors that its post-pandemic business can stand on its own, and Goldman Sachs appears to be asking for more proof before getting more bullish on the stock.